StockNews.AI
BIO
StockNews.AI
204 days

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

1. Bio-Rad will report Q4 2024 results on February 13, 2025. 2. Management will host a conference call to discuss the results. 3. A live webcast of the call will be available on Bio-Rad's investor site. 4. Bio-Rad had $2.7 billion in revenues in 2023. 5. Their customer base includes major research institutions and hospitals.

3m saved
Insight
Article

FAQ

Why Neutral?

Quarterly results are anticipated but not expected to significantly change investor sentiment. Past quarterly reports have shown consistent performance without major stock price fluctuations.

How important is it?

Earnings reports can influence stock performance; however, previous steady performance suggests a limited impact.

Why Short Term?

The impact might be observed immediately after the earnings call. Similar past earnings calls showed immediate stock price reactions.

Related Companies

BIOBIO.B
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year of 2024 on Thursday, February 13, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call will also be available in the "Investor Relations" section of the company’s website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up to a year. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

Related News